Related Experiment Video

Updated: Aug 30, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

[Cardiologic and diabetologic aspects of therapy with angiotensin receptor blocking agents]

Gábor Winkler1, György Jermendy, Lajos Matos

  • 1Fóvárosi Szent János Kórház II. Belosztály.

Orvosi Hetilap
|November 5, 2003
PubMed

Insights

Angiotensin receptor blockers effectively treat heart failure and hypertension, offering cardio- and renoprotective benefits. These medications are safe and well-tolerated in both diabetic and non-diabetic patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Nephrology

Background:

  • Congestive heart failure (CHF) and hypertension are significant cardiovascular diseases.
  • Diabetes mellitus complicates management and increases cardiovascular risk.
  • Angiotensin receptor blockers (ARBs) are a class of antihypertensive drugs.

Purpose of the Study:

  • To review the efficacy and benefits of ARBs in patients with CHF and hypertension.
  • To evaluate the specific application and safety of ARBs in patients with diabetes mellitus.

Main Methods:

  • Systematic review of studies adhering to evidence-based medicine principles.
  • Analysis of clinical trial data on ARB efficacy, tolerability, and safety.
  • Focus on outcomes in diabetic and non-diabetic populations.

Main Results:

  • ARBs demonstrate significant efficacy in managing CHF and hypertension.
  • These agents exhibit good tolerability and a favorable side effect profile.
  • Cardioprotective and renoprotective properties of ARBs are well-supported.
  • ARBs are confirmed as safe for both diabetic and non-diabetic individuals.

Conclusions:

  • ARBs are effective and safe therapeutic options for patients with CHF and hypertension.
  • The benefits of ARBs extend to diabetic patients, with demonstrated safety and efficacy.
  • ARBs offer significant cardio- and renoprotective advantages, improving patient outcomes.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...